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Following two decades of research after
the first clinical reports that a sleep dis-
turbance can precede signs and motor
symptoms of Parkinson’s disease (PD)
(Schenck et al., 1996), studies examin-
ing sleep at the cellular and systems-wide
level in PD-diagnosed and preclinical PD
patients have lead to the belief among sleep
researchers that disturbed sleep occurs
long before PD diagnosis and could be
a predictor of the disease [For exam-
ple, see (Postuma et al., 2009a,b; Hansen
et al., 2013)]. More excitingly, these stud-
ies have led to the tantalizing conclusion
that aggressive treatment of sleeping dis-
orders could actually delay progression of
PD. However, while clinicians fully expect
presence of sleeping disorders in their
PD-diagnosed patients and manage these
complaints (Jahan et al., 2009; Diederich
and McIntyre, 2012; Klingelhoefer et al.,
2014), the possibility of exploitation of
the link between PD and sleeping dis-
orders for pre-clinical PD diagnosis or
treatment approaches designed to delay
motor symptoms of PD has not gone far
outside the sleep research field. Despite
the fact that there is a significant litera-
ture comprised of human epidemiological
and post-mortem studies, as well as ani-
mal studies, which have correlated vary-
ing manifestations of sleep disorders or
changes in neural areas controlling sleep,
as preceding or simultaneous with PD
[For example, see (Arnulf et al., 2002,
2008; Korczyn, 2006; De Cock et al., 2008;
Stavitsky and Cronin-Golomb, 2011)],
clinicians fail to strongly consider that a
patient presenting with a sleeping disorder
has a higher risk of later life development
of PD and that, therefore, these patients
should be carefully monitored for even-
tual onset of the classic signs of neurode-
generative diseases such as PD. Nor is it
standard practice to suggest prophylactic
approaches in these patients to curb onset
of PD.
Why is the link between sleep dis-
orders and eventual appearance of the
classic signs of PD and the possibility
that treatment could delay PD onset not
been made clinically? Clinical acceptance
of this link and of the idea that treat-
ment of sleeping disorders could stave off
PD onset would be facilitated by positive
findings from longitudinal studies with
human patients focused on elucidating
whether there exists a strong association
and/or causality between sleeping disor-
ders and PD and whether aggressive man-
agement of the sleeping disorder appears
to delay appearance of classic PD signs.
However, performing these studies raises
ethical issues, especially if, in an attempt
to provide compelling evidence for causal-
ity, preventative interventions are given to
one group of subjects and not another.
Baring these studies, convincing evidence
could be gained of the link from improved
monitoring of the neurological progress of
patients with sleeping disorders in com-
bination with imaging studies focused on
full characterization of changes in neural
regions controlling sleep which occur in
patients eventually presenting with PD.
But, the question is which behavioral
state disorder(s) should be monitored for
predictive and possibly therapeutic value
in PD. Arguably, the most well-established
association of presence of a sleeping dis-
order preceding any defining signs of PD
is the occurrence of Rapid Eye Movement
(REM)-Sleep Behavior Disorder (RBD),
which is a motor disorder characterized
by aberrant motor activity during the
phase of sleep known as REM, years
before PD diagnosis (Schenck et al., 2002;
Schenck and Mahowald, 2002; Diederich
and McIntyre, 2012). In a group of RBD
patients, epidemiological studies revealed
that nearly 80% of those eventually devel-
oped alpha-synucleinopathies such as PD,
leading to the suggestion that RBD may
represent a prodromal PD sign, indicating
a phase present 2–13 years before appear-
ance of the more classic signs of motor
symptomology (Schenck et al., 1996;
Tippmann-Peikert et al., 2006; Postuma
et al., 2009a,b; Fantini et al., 2011). Animal
models of PD have contributed compelling
evidence that there is a link between sleep
and PD, and have shown motor changes
associated with REM reminiscent to those
of RBD in humans (Verhave et al., 2011).
Since RBD can occur years before the
onset of PD motor symptoms, while pres-
ence of motor disturbances while awake
is currently the principal diagnosis crite-
ria of PD, an even better understanding
of the disturbances of the motor control
of sleep in RBD preceding motor dys-
function in wakefulness gained from lon-
gitudinal studies in humans and studies
using animal models of PD, could pave
the way toward development of a robust,
reliable preclinical sleep-related marker of
eventual onset of PD.
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However, RBD is not the only sleep-
ing disorder associated with PD, as sleep-
related symptomology beyond RDB is
reported to be present in 60–90% of PD
and although the temporal relationship
with PD has not been widely studied
in all of these disorders, these symp-
toms may actually be present quite a bit
earlier than appearance of waking state
motor symptoms. Restless leg syndrome
(RLS), an uncontrollable urge to move the
legs in sleep, was found in patients pre-
symptomatic of PD and from the first
prospective study of its type, severe RLS
was found to be associated with a higher
risk of later life development of PD (Wong
et al., 2014). Excessive daytime sleepiness
(EDS), which is characterized by a persis-
tent sleepiness due to a lack of adequate
sleep, but can also occur when adequate
night-time rest is achieved, has been con-
sidered as a premotormarker for the devel-
opment of PD (Abbott et al., 2005; Gao
et al., 2011) and recent findings in ani-
mal models suggest that occurrence of
EDS could participate in development of
the pathophysiology associated with PD
(Barraud et al., 2009; Verhave et al., 2011).
Sleep is controlled in a circadian fash-
ion, and studies have indicated that there
are early changes in the circadian control
of sleep associated with PD (Breen et al.,
2014), which may precede evidence of
motor dysfunction. What all these afore-
mentioned disorders have in common is
that when present, they lead to inade-
quate sleep, which is interesting in light of
recent theories in the sleep field regarding
the function of sleep as a time of brain
“clean up.” These theories are based in
large part upon findings in rodents that
the glymphatic space, the channel between
neurons and glia, widened during sleep
(Xie et al., 2013) and that ß-amyloid lev-
els in sleep deprived mice were higher
than those in control animals (Kang et al.,
2009). Therefore, later life development of
symptoms associated with neurodegener-
ative diseases may source, in part, from
presence of sleeping disorders which lead
to inadequate rest underlying a reduced
opportunity for flushing of degeneration-
associated proteins from the extracellular
neuron-glial space. When taken together,
the data suggest that better studies need
to be conducted to determine to what
extent these disorders affecting sleep are
associated with, and precede, the motor
symptoms of PD to determine their use-
fulness as a clinical diagnostic tool, and
whether their management would be fruit-
ful in abatement of PD development.
Based on data presently available, sleep
disorders appear to precede the motor
deficits of PD by several years; there-
fore, it is parsimonious to assume that
these manifestations of aberrant con-
trol of the phenomenology of sleep are
directly due to degeneration in neural
regions importantly involved in control of
sleep. Evidence for degeneration in neu-
ral regions that are known to control
sleep behavior that occurs prior to loss
of dopamine-containing striatal neurons,
which is considered the gold-standard
neural signature of PD, would lend sup-
port to a clinical conclusion that sleeping
disorders can be used as diagnostic tools
for PD. Such evidence exists. Degeneration
has been shown to be present early in PD
in a group of state-related cholinergic neu-
rons within the brainstem. Post-mortem
studies of PD patients have shown a sig-
nificant loss of cholinergic neurons of the
mesopontine tegmentum (MPCH) which
via an extensive cholinergic innervation of
rostral and caudal targets is believed to
control phenomenology of REM, includ-
ing motor tone and cortical activity, and
data suggests that the degree of loss of the
cholinergic neurons of theMPCH could be
associated with the severity of PD symp-
toms (Zweig et al., 1989). Loss of MPCH
neurons would be predicted to manifest
in motor behavior dysfunctions during
REM similar to those seen prior to PD,
such as RBD. Interestingly, the MPCH has
been the target of therapeutic stimulation
to successfully alleviate gait disorders in
fully developed PD believed to be due, in
part, to loss of coherent oscillatory activ-
ity in striatal and cortical regions due to
MPCH dysfunction. However, in addition
to improving gait, implantation of elec-
trodes for deep brain stimulation of the
pedunculopontine tegmentum within the
MPCH has also been found to normal-
ize several sleep parameters even up to
1 year post surgery (Peppe et al., 2012).
MPCH neurons are not only involved in
control of sleep but they are also believed
to be importantly involved in generation of
gamma activity underlying aroused elec-
trical cortical activity. If MPCH neurons
are lost very early in PD, as suggested by
the early appearance of abnormal motor
behavior in sleep, it also suggests that
patients with preclinical signs of PD would
show significant aberrations in their abil-
ity to direct internal attention and focus on
cognitive and motor tasks. However, stud-
ies are lacking on early indications of loss
of attentional processes in these patients
prior to appearance of striatal motor
signs.
While it is known from post-mortum
studies that degeneration of MPCH neu-
rons, along with other neurons involved
in state control, such as arousal-related
orexinergic neurons of the hypothalamus
(Thannickal et al., 2007), occurs in PD,
the etiology and time-line of this cell
loss, which likely occurs prior to the hall-
mark loss of dopamine-containing cells
of the striatum is less well-understood.
Appreciation of the early appearance of
sleep and arousal related symptomology in
PD should drive intensive focus in research
investigations of disease-related neurode-
generation of the exact course of loss of
neurons in regions of the brain controlling
state in patients presenting with behav-
ioral state disorders. To this goal, improved
imaging technology has the potential to
increase our understanding of the rela-
tionship of degeneration of the brainstem
and the hypothalamus and the appear-
ance of disorders of sleep before emer-
gence of the distinguishing motor signs
leading to diagnosis. Hopefully, with con-
tinued improvement of this technology,
a correlation can be made between non-
striatal neuronal degeneration, behavioral
state symptomology and PD in an attempt
to develop criteria for earlier recognition
of a high likelihood of later development
of neurodegenerative disease, which could
suggest an aggressive, possibly counteract-
ing treatment of the disorder of state.
In light of findings from clinical and
animal studies, we are supportive of the
opinion that not only is the disorder of
RBD an early marker of PD, but that
also other behavioral state disorders such
as RLS, EDS and circadian system dys-
functions, demonstrate the potential to
be early markers of PD and should be
exploited as reliable indicators for pre-
clinical PD. Targeted investigations which
should include imaging techniques are
expected to provide more accurate data
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upon which clear conclusions of the co-
occurrence of sleeping disorders and PD
can be drawn, and upon which reason-
able underlying mechanisms can be deter-
mined. The presence of behavioral state
disorders in animal models of PD indi-
cates that more invasive detailed studies
of the relationship of dysfunctioning in
brainstem nuclei involved in sleep and
arousal and the motor control of sleep
can be performed, providing more con-
clusive evidence of the sleep-PD link.
When taken together, this work will go
a long way in convincing clinicians that
sleep disorders are preclinical markers of
PD. Such an awareness will likely lead
to increased observations by practition-
ers of the relationship of PD and sleep,
which will enhance detection of sleep
abnormalities, which will serve to feed-
forward and advance the use of presence
of these disorders as preclinical markers
of PD. Detection of PD before the classic
motor signs offers the very real possibil-
ity of application of earlier, and perhaps
more refined, therapies for both PD and
quite possibly, the associated behavioral
state disorders appearing before PD motor
symptoms. More intriguingly perhaps is
the possibility that treatment of disorders
of sleep could slow the progression of the
disease.
ACKNOWLEDGMENT
The authors acknowledge the Science
Without Borders Program, Brazil for
a PhD stipend to Altair Brito dos
Santos and the Philip Morris External
Research Program for funding to Kristi A.
Kohlmeier.
REFERENCES
Abbott, R. D., Ross, G. W., White, L. R., Tanner, C. M.,
Masaki, K. H., Nelson, J. S., et al. (2005). Excessive
daytime sleepiness and subsequent development of
Parkinson disease. Neurology 65, 1442–1446. doi:
10.1212/01.wnl.0000183056.89590.0d
Arnulf, I., Konofal, E., Merino-Andreu, M., Houeto,
J. L., Mesnage, V., Welter, M. L., et al. (2002).
Parkinson’s disease and sleepiness: an integral
part of PD. Neurology 58, 1019–1024. doi:
10.1212/WNL.58.7.1019
Arnulf, I., Leu, S., and Oudiette, D. (2008).
Abnormal sleep and sleepiness in Parkinson’s
disease. Curr. Opin. Neurol. 21, 472–477. doi:
10.1097/WCO.0b013e328305044d
Barraud, Q., Lambrecq, V., Forni, C., McGuire,
S., Hill, M., Bioulac, B., et al. (2009). Sleep
disorders in Parkinson’s disease: the contri-
bution of the MPTP non-human primate
model. Exp. Neurol. 219, 574–582. doi:
10.1016/j.expneurol.2009.07.019
Breen, D. P., Vuono, R., Nawarathna, U., Fisher, K.,
Shneerson, J. M., Reddy, A. B., et al. (2014).
Sleep and circadian rhythm regulation in early
Parkinson disease. JAMA Neurol. 71, 589–595. doi:
10.1001/jamaneurol.2014.65
De Cock, V. C., Vidailhet, M., and Arnulf, I. (2008).
Sleep disturbances in patients with parkinson-
ism. Nat. Clin. Pract. Neurol. 4, 254–266. doi:
10.1038/ncpneuro0775
Diederich, N. J., and McIntyre, D. J. (2012). Sleep
disorders in Parkinson’s disease: many causes, few
therapeutic options. J. Neurol. Sci. 314, 12–19. doi:
10.1016/j.jns.2011.10.025
Fantini, M. L., Farini, E., Ortelli, P., Zucconi, M.,
Manconi, M., Cappa, S., et al. (2011). Longitudinal
study of cognitive function in idiopathic REM
sleep behavior disorder. Sleep 34, 619–625. doi:
10.5665/Sleep.3050
Gao, J., Huang, X., Park, Y., Hollenbeck, A., Blair,
A., Schatzkin, A., et al. (2011). Daytime nap-
ping, nighttime sleeping, and Parkinson dis-
ease. Am. J. Epidemiol. 173, 1032–1038. doi:
10.1093/aje/kwq478
Hansen, I. H., Marcussen, M., Christensen, J. A.,
Jennum, P., and Sorensen, H. B. (2013). Detection
of a sleep disorder predicting Parkinson’s dis-
ease. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2013,
5793–5796. doi: 10.1109/EMBC.2013.6610868
Jahan, I., Hauser, R. A., Sullivan, K. L., Miller, A.,
and Zesiewicz, T. A. (2009). Sleep disorders in
Parkinson’s disease. Neuropsychiatr. Dis. Treat. 5,
535–540. doi: 10.2147/NDT.54578
Kang, J. E., Lim, M. M., Bateman, R. J., Lee, J. J.,
Smyth, L. P., Cirrito, J. R., et al. (2009). Amyloid-
beta dynamics are regulated by orexin and the
sleep-wake cycle. Science 326, 1005–1007. doi:
10.1126/science.1180962
Klingelhoefer, L., Sokolov, E., and Chaudhuri, K. R.
(2014). Therapeutic options for nocturnal prob-
lems in Parkinson’s disease and atypical parkin-
sonian disorders. J. Neural Transm. 121 Suppl. 1,
S25–S31. doi: 10.1007/s00702-014-1202-6
Korczyn, A. D. (2006). Management of sleep problems
in Parkinson’s disease. J. Neurol. Sci. 248, 163–166.
doi: 10.1016/j.jns.2006.05.041
Peppe, A., Pierantozzi, M., Baiamonte, V., Moschella,
V., Caltagirone, C., Stanzione, P., et al. (2012).
Deep brain stimulation of pedunculopontine
tegmental nucleus: role in sleep modula-
tion in advanced Parkinson disease patients:
one-year follow-up. Sleep 35, 1637–1642. doi:
10.5665/sleep.2234
Postuma, R. B., Gagnon, J. F., Vendette, M., Fantini,
M. L., Massicotte-Marquez, J., and Montplaisir,
J. (2009b). Quantifying the risk of neurodegen-
erative disease in idiopathic REM sleep behav-
ior disorder. Neurology 72, 1296–1300. doi:
10.1212/01.wnl.0000340980.19702.6e
Postuma, R. B., Gagnon, J. F., Vendette, M., and
Montplaisir, J. Y. (2009a). Markers of neurodegen-
eration in idiopathic rapid eye movement sleep
behaviour disorder and Parkinson’s disease. Brain
132, 3298–3307. doi: 10.1093/brain/awp244
Schenck, C. H., Bundlie, S. R., Ettinger, M. G., and
Mahowald, M. W. (2002). Chronic behavioral dis-
orders of human REM sleep: a new category
of parasomnia. 1986 [classical article]. Sleep 25,
293–308. doi: 10.1016/JMCNA.2010.02.010
Schenck, C. H., Bundlie, S. R., and Mahowald, M.
W. (1996). Delayed emergence of a parkinsonian
disorder in 38% of 29 older men initially diag-
nosed with idiopathic rapid eye movement sleep
behaviour disorder. Neurology 46, 388–393. doi:
10.1212/WNL.46.2.388
Schenck, C. H., and Mahowald, M. W. (2002). REM
sleep behavior disorder: clinical, developmental,
and neuroscience perspectives 16 years after its for-
mal identification in SLEEP. Sleep 25, 120–138. doi:
10.1016/J.Sleep.2009.06.008
Stavitsky, K., and Cronin-Golomb, A. (2011). Sleep
quality in Parkinson disease: an examination of
clinical variables. Cogn. Behav. Neurol. 24, 43–49.
doi: 10.1097/WNN.0b013e31821a4a95
Thannickal, T. C., Lai, Y. Y., and Siegel, J. M.
(2007). Hypocretin (orexin) cell loss in
Parkinson’s disease. Brain 130, 1586–1595.
doi: 10.1093/brain/awm097
Tippmann-Peikert, M., Boeve, B. F., and Keegan,
B. M. (2006). REM sleep behavior disor-
der initiated by acute brainstem multiple
sclerosis. Neurology 66, 1277–1279. doi:
10.1212/01.wnl.0000208518.72660.ff
Verhave, P. S., Jongsma, M. J., Van den Berg, R.
M., Vis, J. C., Vanwersch, R. A., Smit, A. B.,
et al. (2011). REM sleep behavior disorder in
the marmoset MPTP model of early Parkinson
disease. Sleep 34, 1119–1125. doi: 10.5665/
SLEEP.1174
Wong, J. C., Li, Y., Schwarzschild, M. A., Ascherio,
A., and Gao, X. (2014). Restless legs syndrome: an
early clinical feature of Parkinson disease in men.
Sleep 37, 369–372. doi: 10.5665/sleep.3416
Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y.,
Thiyagarajan, M., et al. (2013). Sleep drives
metabolite clearance from the adult brain. Science
342, 373–377. doi: 10.1126/science.1241224
Zweig, R. M., Jankel, W. R., Hedreen, J. C., Mayeux,
R., and Price, D. L. (1989). The pedunculopontine
nucleus in Parkinson’s disease. Ann. Neurol. 26,
41–46. doi: 10.1002/ana.410260106
Conflict of Interest Statement: The authors declare
that the research was conducted in the absence of any
commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 11 August 2014; accepted: 20 September 2014;
published online: 09 October 2014.
Citation: dos Santos AB, Barreto GE and Kohlmeier
KA (2014) Treatment of sleeping disorders should be
considered in clinical management of Parkinson’s dis-
ease. Front. Aging Neurosci. 6:273. doi: 10.3389/fnagi.
2014.00273
This article was submitted to the journal Frontiers in
Aging Neuroscience.
Copyright © 2014 dos Santos, Barreto and Kohlmeier.
This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licen-
sor are credited and that the original publication in
this journal is cited, in accordance with accepted aca-
demic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Aging Neuroscience www.frontiersin.org October 2014 | Volume 6 | Article 273 | 3
